Ontorpacept (Research-Grade) is a research-grade biosimilar monoclonal antibody targeting CD47. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical).
Fusion-[human activin receptor type 2-A (activin receptor type IIA, ACTR-IIA) extracellular domain (ECD) fragment (1-109) engineered varian]2-IgG1-Fc (Fragment constant)
